Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AssigneeRhone-Poulenc Rorer Pharmaceuticals Inc.
InventorsMichael R. Myers, Alfred P. Spada, Martin P. Maguire, Paul E. Persons
Life of this patent
Estimating the term…
Abstract
This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation using said quinazoline compounds and their use in pharmaceutical compositions is described.
Claims14
A method of inhibiting cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising administering to a patient a compound of the formula:
- ##STR89## wherein Ar is selected from substituted or unsubstituted phenyl, .alpha.-naphthyl, .beta.-naphthyl, indazolyl, indanyl, pyrazolyl, pyridinyl, indol-3-yl, benzodioxan-6-yl, 1,2,3,4-tetrahydroquinolin-1-yl, or 2,3-dihydroindol-1-yl where the substituents may be located at any appropriate position of the ring system and are described by R;
- X is a bond, O, S, NHCH.sub.2 or NR.sub.4 ;
- R independently includes hydrogen, alkyl, hydroxy, alkoxy, phenyl, aralkyl, alkylsulphonyl, haloalkyl or halo;
- R.sub.5 is hydrogen or alkoxy;
- R.sub.6 and R.sub.7 are alkoxy;
- and
- R.sub.4 is hydrogen, methyl, ethyl or benzyl;
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- 4-(3,4,5-trimethoxyphenylamino)-6,7-dimethoxyquinazoline,
- 4-(N-methyl-3,4,5-trimethoxyanilino)-6,7-dimethoxyquinazoline,
- 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline,
- 4-(N-methyl-4-chloroanilino)-6,7-dimethoxyquinazoline,
- (6,7-dimethoxyquinazolin-4-yl)methyl-(3-trifluoromethylphenyl)amine,
- (3-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)methylamine,
- N-phenyl-N-(6,7,8-dimethoxyquinazolin-4-yl)methylamine,
- (3-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)ethylamine,
- (6,7-dimethoxyquinazolin-4-yl)methyl-p-tolyl-amine,
- (4-methoxybenzyl)-(6,7-dimethoxyquinazolin-4-yl)amine,
- (3,5-dimethoxybenzyl)-(6,7-dimethoxyquinazolin-4-yl)amine, and
- 6,7-dimethoxy-4-(N-methylanilino)quinazoline;
- or a pharmaceutically acceptable salt thereof.
A compound which is 4-(pyrazol-3-ylamino)-6,7-dimethoxyquinazoline or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- (6,7-dimethoxyquinazolin-4-yl)-5-indazolylamine,
- 4-N-(5-indanyl)amino!-6,7-dimethoxyquinazoline,
- 4-(3,6-dioxananilino)-6,7-dimethoxyquinazoline,
- 6,7-dimethoxy-4-(.alpha.-naphthylamino)quinazoline, and
- 6,7-dimethoxy-4-(.beta.-naphthylamino)quinazoline;
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- 4-(3,4,5-trimethoxyphenoxy)-6,7-dimethoxyquinazoline,
- 4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline,
- 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline, and
- 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline;
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- 4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline,
- 4-(naphthalen-1-yl)-6,7-dimethoxyquinazoline,
- 4-(naphthalen-2-yl)-6,7-dimethoxyquinazoline,
- 4-(3-fluoro-4-methoxyphenyl)-6,7-dimethoxyquinazoline,
- 4-(3-phenylphenyl)-6,7-dimethoxyquinazoline,
- 4-(2-methoxypyridin-5-yl)-6,7-dimethoxyquinazoline,
- 4-(1-benzylindol-3-yl)-6,7-dimethoxyquinazoline,
- 4-(indol-3-yl)-6,7-dimethoxyquinazoline,
- 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline,
- 4-(1-methylsulphonylindol-3-yl)-6,7-dimethoxyquinazoline,
- (.+-.)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazolin e,
- 4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline, and
- 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.